Side-by-side · Research reference
BronchogenvsCortagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED16/35 cited
BAnimal-MechanisticHUMAN-REVIEWED11/35 cited
Bronchogen
Tetrapeptide Bioregulator · Khavinson-School
Research models: tissue culture / parenteral
Cortagen
Bioregulatory Tetrapeptide · Khavinson-School
Injectable · Animal models
01Mechanism of Action
Parameter
Bronchogen
Cortagen
Primary target
Bronchial epithelial cellsKuzubova 2015
Cerebral cortex tissue — molecular targets under investigation
Pathway
Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration
Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modificationKozina 2007
Downstream effect
Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015Titova 2017
Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissueKozina 2007Anisimov 2004
Feedback intact?
—
—
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework
Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation CortexinAnisimov 2004
Antibody development
—
—
02Dosage Protocols
Parameter
Bronchogen
Cortagen
Effective concentration (culture)
0.05 ng/mLZakutskiĭ 2006
Demonstrated in organotypic tissue culture of bronchial explants.
—
Treatment duration (animal)
1 month (30 days)Kuzubova 2015Titova 2017
Course duration in rat COPD models.
—
Evidence basis
Animal models (rat) / organotypic cultureTitova 2017Kuzubova 2015Zakutskiĭ 2006
No human clinical trials reported in available literature.
Animal mechanistic studies
Tissue specificity
Selective for bronchopulmonary tissue
Part of Khavinson organ-specific bioregulator series.
—
Animal model dose (rat)
—
Injection protocol (dose not specified in abstracts)
Multiple injections over study period.
Avian model dose (chicken)
—
40-day injection courseKuznik 2008
Compared to epithalon in hypophysectomized and aged birds.
Human peripheral nerve study
—
Therapeutic course (protocol details not provided)
Posttraumatic recovery context — reference cited but not detailed.
Route
—
Injectable (inferred from animal protocols)
04Side Effects & Safety
Parameter
Bronchogen
Cortagen
Animal safety profile
No adverse effects reported in published rat studies
Limited safety data; only animal models available.
—
Human data
Absent — no clinical trials in humans reported
—
Long-term effects
Unknown — maximum study duration 30 days in animals
—
Antioxidant suppression
—
Suppression of antioxidant activity noted alongside LPO reductionKozina 2007
Mechanism unclear — possible homeostatic adaptation.
Immune/hemostasis effects
—
No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon)Kuznik 2008
Epithalon reversed deficits; cortagen did not.
Human safety data
—
No adverse events reported in peripheral nerve recovery context
Limited detail in available abstracts.
05Administration Protocol
Parameter
Bronchogen
Cortagen
1. Research context only
Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.
Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.
2. Animal model protocol
In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017Kuzubova 2015
Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.
3. Organotypic culture
Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006
Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.
4. Khavinson bioregulator tradition
Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.
Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.